ATTEMPTS to evaluate tetra-sodium 2-methyl-i : 4-naphthohydroquinone diphosphate (Compound I, Synkavit) as a radiosensitiser in the radiotherapy of malignant tumours have been in progress since November, 1946. At first the compound was used alone and in conjunction with palliative X-ray therapy in some very advanced cases. It soon became evident that in general the compound alone had no therapeutic effect in malignant tumours. Then a general survey was undertaken of the use of large doses of Compound I mainly in conjunction with radiotherapy in patients with various types of advanced malignant tumours. At the same time, all cases of inoperable carcinoma of the bronchus were treated, if possible, by the combination of X-ray therapy and Compound I; the results were assessed mainly by survival times from the first X-ray treatment and the first sympton and were compared with those which had been obtained previously in the same department with X-ray therapy only, and which were very similar to the depressing results obtained by most of the workers. Slowly the difficulties of this type of clinical investigation were appreciated. Moreover in 1950 erratic results were encountered both in the clinical trials and in animal experiments. It seems likely that these findings were attributable to the thermal instability of Compound I in aqueous solution in the absence of oxygen (Mitchell and SimonReuss, 1952). Much more consistent results have been obtained since the ampoules have been stored in a refrigerator at about 30 C.
The results of the earlier studies have been reported by Mitchell (1948 Mitchell ( , 1949a Mitchell ( , 1949b Mitchell ( , 1950 Mitchell ( , 1951 . This work has been criticised by Gellhorn and Gagliano (1950) . Otte (1949) reported briefly on the combination of X-ray therapy and some synthetic vitamin K substitutes in the treatment of 300 patients with advanced malignant tumours and claimed improved palliation. Berkman (1951) obtained results very similar to those of Mitchell by the combined use of X-ray therapy and Synkavit.
Selection of types of malignant tumour for investigation.
It is suggested that a practical minimum requirement for usefulness of a radiosensitising chemical agent is that its employment in combination with radiotherapy should produce a mean survival time after treatment double that after radiotherapy only, for the type of malignant tumour treated. Hence taking into account the frequency distribution of the survival times, it is likely to be necessary to observe the cases treated by combined therapy for an interval of at least 6 times the mean survival after radiotherapy only. To this time must be added the time necessary to accumulate an adequate number of cases. This approach is limited to the study of types of malignant tumour in which the results of present methods of treatment are bad and in which the time of survival is short. Inoperable carcinoma of the bronchus is an obvious choice for investigation It is the only common type of malignant disease with a very short natural history. Despite advances, only a small proportion of all cases of carcinoma of the bronchus are curable by surgery. Untreated patients are often very miserable. The results of treatment of inoperable cases by present methods, including radical X-ray therapy, are poor. Nevertheless X-ray therapy in general has sufficient palliative value apart from prolongation of life per se, to justify attempts to improve this.
With X-ray therapy only, inoperable carcinoma ofthe bronchus appears to have a a rather uniform natural history. The results of many workers have been reviewed in a number of papers (e.g., Bjork, 1947;  Shorvon, 1947 : Ariel et al., 1950 . In one of the earliest studies Schinz and Zuppinger (1937) reported that for 69 cases, the mean survival time after the beginning of X-ray treatment was 4-4 months; 16 cases (23 per cent) lived more than 6 months and 4 cases more than 1 year. Dobbie (1944) found that of 111 cases receiving palliative X-ray therapy, 26 per cent lived more than 6 months, and of 48 cases treated by radical X-ray therapy, 54 per cent lived more than 6 months after treatment. Fulton (1949) reported the following mean survival times from the onset of symptoms: for 915 untreated cases 7-6 months, for 199 cases receiving palliative X-ray therapy 9 0 months and for 190 cases treated by radical X-ray therapy, 14-7 months. The largest published series of treated cases appears to be that of Ariel et al (1950) .
The duration of life from the onset of symptoms of 723 patients who received X-ray therapy and for whom adequate data were available averaged 12-8 months. Of 816 patients receiving X-ray therapy, the average duration of life after the first X-ray treatment was 4-2 months. Of these, histological evidence was obtained in 245 patients and their average survival from the first symptom was 14-3 months and from the beginning of X-ray treatment 4-5 months. From Fig. 7 of this paper, it can be deduced that of 729 patients, only 45 survived 8 months, 20 survived 12 months, 8 survived 18 months and none survived 3 years following X-ray therapy. In this series, the best survival rate-4-7 months-was in a group of 80 patients who received a total dose as measured in air of 5000-6000 r;
higher and lower doses were associated with poorer results. The relation between survival time and tumour dose (and histology), has often been discussed, e.g., by Tenzel (1941) , Adelman (1952 Boag, 1948 Boag, , 1949 Boag, , 1950 PRELIMINARY GENERAL SURVEY The results-of the preliminary general survey summarised in Table I suggests  that the proportion of cases showing unexpectedly good clinical response is greater   22   315   316 with radiotherapy combined with the compound administered by intravenous injection than with radiotherapy combined with the compound administered by intramuscular injection. It is emphasised that this conclusion must not be regarded as more than suggestive.
Of the 131 cases verified histologically, 11 survived 4 years or more after treatment. Of these, 5 cases showed an unexpectedly good response. Three of these were treated by means ofradical X-ray therapy combined with intravenous compound-one case of advanced carcinoma of the ovary and body of uterus with peritoneal metastases; one case of advanced reticulo-sarcoma of bones and one .1-case of advanced netiro-fibro-lipo-sarcoma of neck. One case of advanced carcinoma of the body of the uterus was treated by means of palliative X-ray therapy combined with intravenous compound, and one case of carcinoma of the tongue recurrent after previous X-ray therapy was treated successfully by radical X-ray therapy combined with intramuscular compound.
Of the 56 cases not confirmed histologically three survived more than 4 years after treatment. Two of these showed an unexpectedly good response; one was a woman aged 46, who had a Stage IV carcinoma of the breast with supraclavicular glands, and was treated by means of radical X-ray therapy combined with intramuscular compound, and the other was a case of a mixed parotid tumour which had failed to respond to further X-ray therapy, but appeared to be checked and rendered quiescent by intravenous compound onlv. An unexpected finding as shown in Table I for histologically positive cases is that 8 of 1.) cases recurrent after radiotherapy showed an unespectedly good result when treated with intravenous compound only. This is the only group in which any substantial proportion of cases appeared to improve with the use of the compound alone; this finding requires confirmation. It is emphasised that in general the compound alone has no therapeutic effect in malignant tumours.
Preliminary Clinical Trials in Inoperable Carcinoma of the Bronchus
The initial studies of the ancillary use of Compound I on the survival times of inoperable cases of carcinoma of the bronchus treated by X-ray therapy (Mitchell, 1948 (Mitchell, , 1951 were probably essential as a preliminary step to the design of a more satisfactory clinical trial. It is useful to summarise the end resuLlts of these studies.
An attempt was made to study the influence of the ancillary use of the compound on the results of X-ray therapy by measurement of the time of survival both after the first symptom and after the first X-ray treatment and comparison of the survival times in the control group of cases, which was treated by X-ray therapy only and in the treated group which received X-ray therapy together with the compound. The results are treated by statistical methods. It is suggested that estimation of the survival times, especially that from the beginning of X-ray therapy, is the most reliable criterion for objective assessment of the results of treatment. Special attention has been paid to the influence of the extent of the disease, age and sex, the histology, the minimum tumour dose and overall time of the X-ray therapy and the details of administration of the compound. The general principles involved in the consideration of these factors are essentially the same in these preliminary studies as in the later clinical trials and except where relevant, will be discussed in this connection. An attempt has been made to compare the effects of the compound as a radio sensitiser when administered by intramuscular and by intravenous injection.
Selection of cases.
The group defined as the treated group of cases of inoperable carcinoma of the bronchus received X-ray therapy together with the compound which was administered by intravenous and/or intramuscular injection, together with supplementary oral administration in a few cases. In the cases recorded, the first X-ray dose in the combined treatment was given in the interval from May 1, 1947
to December 31, 1949 inclusive. The results of treatment were reviewed as from December 31, 1952. This group of cases of inoperable carcinoma of the bronchus comprises all those cases referred in which the diagnosis is accepted as proven according to the criteria given below, with the exclusion of patients not likely to benefit by palliative X-ray therapy. No technically operable cases and no postoperative cases are included. The control group consists of those cases of inoperable carcinoma of the bronchus selected according to the same criteria, which were treated by X-ray therapy only, using similar methods, in the same department between 1943 and May, 1947. The difficulties of this method of providing a control group are recognised and include the possibility of introduction of serious errors of sampling. The use of alternate cases as controls was attempted but was abandoned as impractical. However, it has been shown that the relevant properties of the control and treated groups apart from the length of survival after treatment are substantially the same. It is found that the results of X-ray treatment in the present control group are substantially identical with those obtained in two large published series. (Fulton 1949 , Ariel et al., 1950 .
Classification of Cases.
In both control and treated groups the most important cases are those completely " verified histologically " by the following methods:
(a) bronchial biopsy; this sub-group consists of 11 control cases and 26 treated cases. (b) post-mortem examination; this sub-group consists of 6 control cases and 2 treated cases.
(c) biopsy of a homolateral supra-clavicular node, in conjunction with typical bronchoscopic appearances; in this sub-group there was one control case and one treated case.
The histological examination of the bronchial biopsy specimens was inconclusive. (d) the finding of cells consistent with malignancy in the sputum, together with typical bronchoscopic appearances; there was only one case, a control, in this sub-group (Table II) and in this case there were terminal metastases in the liver.
Thus of the cases described as " verified histologically," there are in all, 19 in the control group, which was treated by X-ray therapy only, and 29 in the treated group which received X-ray therapy combined with administration of the compound.
The larger proportion of cases verified histologically at post-mortem examination in the control group than in the treated group is associated with the shorter survival time and the larger proportion of cases dying in hospital.
In addition to the " histologically verified " cases, there are groups of control and treated cases in which the diagnosis is reasonably certain though less satisfactorily established. These groups are selected as follows:
(a) cases not verified histologically but with typical bronchoscopic appearances, together with clinical and/or radiological evidence of metastases or infiltration at any stage; this sub-group consists of 7 control cases and 9 treated cases; Selected from these cases are those with no evidence of extra-thoracic spread or metastases in ribs at the first X-ray treatment and those in which the minimum tumour dose was not less than 1200 r. For the present purpose, cases treated surgically at any stage, and female patients are excluded. Survival is estimated in months to the nearest month from the first X-ray treatment and also from the first symptom.
Number of cases surviving 8 months or Group.
more from first X-ray treatment. * In this group is included one case surviving 4 months from the first X-ray treatment and 10 months from the first symptom which was given intra-muscular compound because of incorrect suspicion of cerebral metastases. The difference between the proportion surviving 8 months or more from the first X-ray treatment in the two series is statistically significant; for the pooled Groups (a), (b) and (c), x[1]2 = 10-76, so that P = 0-001, and for the pooled Groups (a) and (b), x[1]2 = 6-891, so that P = 0-009.
Survival from the first symptom is a rather less sensitive and less objective test. In the pooled Groups (a), (b) and (c), the proportions surviving 12 months or more from the first symptom in the series X + I-VS and X + I-MS are respectively 11 /14 and 8/19; X[1]2 = 4-389, so that P = 0-037, which may be regarded as significant.
Number of cases surviving 8 months or Other ca8es.
more from first X-ray treatment. Total number of cases in each group. (a) 
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For the unselected male patients with reasonably certain diagnosis in the pooled Groups (a), (b), (c), (d) and (e), the difference between the proportion surviving 8 months or more from the first X-ray treatment in the two series is statistically significant; x[]2 = 8-867, so that P = 0-003.
The proportions surviving 12 months or more from the first symptom in the series X + I-VS and X + I-MS are respectively 16 /25t and 10/31; XC2 = 4-403, so that P = 0-037, which may be regarded as significant.
t The case marked * above is transferred to the series X + I-MS.
(b) cases with positive histology on biopsy specimens of supraclavicular nodes, cutaneous or other metastases but in which there was no bronchoscopy or the bronchoscopic appearances were not definite; this sub-group consists of 8 control cases and 8 treated cases ; (c) one case (treated) with typical bronchoscopic appearances together with metastases in the skin, confirmed histologically. These additional 15 control and 18 treated cases are usually more advanced and are in general less comparable than the " histologically verified " cases but must be considered with them to give a complete picture. Of the combined series of " confirmed cases," there are in all 34 in the control group, which was treated by X-ray therapy only, and 47 in the treated group, which received X-ray therapy together with the compound. As anticipated the results of treatment of the " confirmed cases " are poorer than those of the " histologically verified " cases.
Other groups of cases which cannot be included in the main part of this investigation may be summarised as follows:
(i) Cases with typical radiological appearances together with metastases at some stage but not verified histologically and in which there was no bronchoscopy or the bronchoscopic appearances were not definite. In these cases the diagnosis can only be regarded as probable. In the control group, there are 12 cases; the mean time of survival is 8-50 months from the first symptom and 3-67 months from the first X-ray treatment. In the treated group, there are 13 cases; the mean times of survival are 12-15 months from the first symptom and 6*31 months from the first X-ray treatment.
(ii) Cases rejected as unsuitable for palliative X-ray therapy. During the control period, there were 18 of these cases, of which 10 were histologically verified and during the period corresponding to the treated group, there were 7 cases of which only one was verified histologically.
The enumeration of rejected cases is unsatisfactory because of selection by the physicians referring these advanced cases.
Hence the total number of cases with a reasonably certain or probable diagnosis of inoperable carcinoma of the bronchus is 131. The control group is drawn from a total of 64 cases, and the treated group from a total of 67 cases.
Histology.
Of the 19 verified control cases, there are 11 cases of stratified carcinoma, of which 7 are squamous and 4 non-squamous, 3 cases of adenocarcinoma, 4 of ana plastic carcinoma and one unclassified. Of the 7 cases of squamous carcinoma, two showed keratinisation.
Of the 29 verified treated cases, there are 17 cases of stratified carcinoma, of which 10 are squamous and 7 non-squamous, 3 cases of adenocarcinoma, 8 of anaplastic carcinoma and one an unusual poorly differentiated lesion.
Of the 10 cases of squamous carcinoma three cases show definite keratinisation; in two further cases there is a suggestion of keratinisation. It is interesting to note that all these cases responded well to treatment.
RESULTS.
The control group was treated by X-ray therapy only, from 1943 to May, 1947. The treated group was treated by X-ray therapy combined with tetra-sodium 2-methyl-I: 4-naphthohydroquinone diphosphate (Compound I, Synkavit) administered by intravenous and/or intramuscular injection from May, 1947 to December, 1949 inclusive.
Cases verified histologically.
Cases were verified histologically mainly by bronchial biopsy and/or postmortem examination.
Control group: X-ray therapy only. 19 cases: mean survival 3*89 months from the first X-ray treatment and 11.00 months from the first symptom.
Only 1 case, who survived 15 months, survived more than 8 months from the first X-ray treatment.
Three cases survived more than 15 months from the first symptom. Treated group: X-ray therapy combined with the compound. 29 cases: mean survival 9*38 months from the first X-ray treatment and 1755 months from the first symptom.
Of these, 15 cases survived more than 18 months and 7 cases more than 15 months from the first treatment; 15 cases also survived more than 15 months from the first symptom.
The survival time from the first X-ray treatment is significantly greater in the treated group (mean survival 9-38 months) than in the control group (mean survival 3589 months)-(n = 46 Student's t = 3.519, P = 0*001; using the logarithms of the survival times, t = 4.046). Even if the cases which survived only one month from the first X-ray treatment are excluded, to meet the criticism of a possible difference in selection of the cases, the difference in survival after the first treatment between the treated group (mean survival 9-68 months) and the control group (mean survival 5-23 months) is still significant (n = 39, t 2*457, P is slightly less than 0-02). Considering the histological classification, the only type providing adequate numbers is the stratified carcinoma. The proportion of cases of stratified carcinoma is almost identical in the control (11/19) and treated (17/29) groups. Of the cases of stratified carcinoma surviving more than 8 months from the first X-ray treatment, there are 1 out of 11 cases ih the control group and 11 out of 17 cases in the treated group; the survival must be regarded as significantly greater in the treated than in the control group; (Xc2= 6-32, P = 0'012).
It is relevant to note that the frequency distribution of survival times after the first X-ray treatment is positively J-shaped for the control group and roughly symmetrical, probably approximating to lognormal for the treated group. There are significantly fewer short survivals in the treated group than in the control group, e.g., of cases surviving 3 months or less after the first X-ray treatment, there were 5/29 in the former and 12/19 in the latter; xC2 =8-67, P = 0-003. It is suggested that this change in frequency distribution provides further evidence for the reality of the radiosensitisation.
The survival time from the first symptom is significantly greater in the treated group (mean survival 17-55 months) than in the control group (mean survival 11.00 months)-(n = 46, t = 2-624, P = 0.012). There is no significant difference between the time interval from the first symptom to the first treatment in the control group (mean interval 7*11 months) and in the treated group (mean interval 8 17 months). It is to be noted that the treated group includes one case, who had a history of 45 months' duration before treatmnent and survived 3 months from the first X-ray treatment.
Within the treated group, 20 cases were treated by X-ray therapy combined with the compound administered by intravenous injection or by both intramuscular and intravenous injection. In this treated sub-group of 20 cases, the mean survival time is 11-05 months and is significantly greater than the mean survival time of 3-89 months in the control group of 19 cases (n -37, t = 4-345, P <0-001).
There is suggestive evidence that X-ray therapy combined with intravenous compound is associated with longer survival after the first X-ray treatment (18 cases, mean survival 11'17 months) than is X-ray therapy combined with intramuscular compound (11 cases, mean survival 6*45 months)-(n = 27, t = 2 106, P = 0-04).
All confirmed cases.
Control group: X-ray therapy only. 34 cases: mean survival 3-82 months from the first X-ray treatment and 10-00 months from the first symptom.
Only 2 cases, which survived 12 and 15 months respectively, survived more than 8 months from the first X-ray treatment and 4 cases survived more than 15 months from the first symptom.
Treated group: X-ray therapy combined with the compound. 47 cases: mean survival 8-72 months from the first X-ray treatment and 15-45 months from the first symptom.
Of these, 18 cases survived more than 8 months and 8 cases more than 15 months from the first X-ray treatment; 16 cases survived more than 15 months from the first symptom.
The survival time from the first X-ray treatment is significantly greater in the treated group (mean survival 8-73 months) than in the control group (mean survival 3*82 months) -(n = 79, t = 3-630, P < 0-001; using the logarithms of the survival times, t = 3-967).
The survival time from the first symptom is also to be regarded as significantly greater in the treated group (mean survival 15-45 months) than in the control group (mean survival 10.00 months)-(n = 79, t = 2*678, P < 0.01).
It is interesting to consider the proportion of cases surviving more than 15 months from the ilrst X-ray treatment out of the total number of cases with reasonably certain or probable diagnosis and including those cases rejected as unsuitable for X-ray therapy during the periods of observation. In these total groups, there are 64 control cases (including 8 rejected) of whom none survived more than 15 months from the first X-ray treatment and 67 treated cases (including 7 rejected) of whom 9 survived more than 15 months. This difference between the control and treated cases is significant (X,2 = 7-25, P = 0008 and excluding the cases rejected, X_2 = 5*73, P = 0.017).
In the group of confirmed cases, 6 control cases and 6 treated cases received radical X-ray therapy. For these control cases, the mean survival time is 14-5 months from the first symptom and 6-3 months from the first X-ray treatment. For the treated cases the mean survival time is greater than 22-5 months from the first symptom and greater than 13*2 months from the first treatment. However, the number of these cases is too small for the observed difference to be taken as a real one with any certainty. It is interesting to note that the mean survival from the first symptom in Fulton's (1949) series of 190 cases treated by radical X-ray therapy was 14 7 months; the closeness of the aggreement is fortuitous.
This preliminary trial suggests that in the treatment of inoperable carcinoma of the bronchus the ancillary use of Compound I produces a small but useful increase in the length of survival. This finding is in accordance with the clinical impressions and the small improvement in length of survival appears to be associated with useful life.
However, this study is not entirely satisfactory in that the control group treated by X-ray therapy only and the treated group which received X-ray therapy combined with the compound, were treated consecutively and not within the same period of time.
Design of a Clinical Therapeutic Trial of a Radiosensitiser. The design of a clinical trial to evaluate any proposed method of treatment of cancer appears to be one of the most important problems in medicine at the present time. The basic principles involved are well understood as a result of the classical statistical studies of Fisher (1925 Fisher ( , 1935 on the design of experiments, and on the work of Hill (1952) on the design of clinical trials. In general, in considering therapeutic trials in the cancer field, the design must be capable of giving a completely convincing statistically significant quantitative result as efficiently as possible with a minimum number of patients and must be acceptable and above reproach from the moral and ethical points of view. The most important single feature of the design is random allocation of the patients to two or more alternative forms of treatment the value of which is being compared. For assessment of the result of treatment, it is necessary to select relevant criteria capable of objective measurement such as the survival time suitably specified. At the same time, it is absolutely essential to provide for each individual patient treatment which is the best possible according to present knowledge. Accordingly, it may be, and probably often will be, necessary to plan to depart from what may be termed the theoretically ideal form of experiment with deliberate sacrifice of some information.
In the present example of the attempted evaluation of tetra-sodium 2-methyl-1: 4-naphthohydroquinone diphosphate (Compound I, Synkavit) as a radiosensitiser in the radio therapy of inoperable carcinoma of the bronchus, cases were allocated at random to one of two alternative forms of treatment, X-ray therapy combined with Compound I administered by intravenous injection (X + I-VS) and X-ray therapy combined with Compound I administered by intramusculrzr injection (X + I-MS). The latter is regarded as the control group.
The preliminary clinical studies and animal experiments suggested that the results of X-ray therapy combined with intramuscular compound (X + I-MS) were slightly better than those of X-ray therapy only, and that with comparable doses of compound it was likely that X + I-VS would produce better results than X + I-MS. The use of X + I-MS as the control group instead of, e.g., X-ray therapy combined with distilled water, almost certainly scarifices a small amount of information but was regarded as essential in order to give to each individual patient the best available proven form of treatment. This type of design of a clinical therapeutic trial must be justified a posteriori. It is necessary to -examine the possible importance of all the various factors which may be relevant including age, sex, extent of the disease at treatment, histology and/or cytology, the minimum tumour dose and overall time of radiotherapy, the total dose and overall time of administration of the compound and in particular the certainty of the diagnosis. Tests of heterogeneity must be made. It does not seem possible to estimate in advance the number of patients required. This will depend on the differences observed between the groups and subgroups. The results are likely to be of sufficient importance to necessitate the use of stringent criteria of significance.
The randomisation was made on the basis of a provisional diagnosis of inoperable carcinoma of the bronchus, made when the patient was first examined by the staff of the Department. Some of the cases were referred with histological evidence from bronchial biopsy. In other cases, there had been no previous investigation and the provisional diagnosis was based on clinical evidence only.
All cases were investigated critically, as necessary, and every effort was made to obtain histological and/or cytological verification of the diagnosis. (1) Stratified carcinoma, either squamous or non-squamous, the degree of keratinisation or differentiation being noted, (2) adenocarcinoma, (3) anaplastic carcinoma, including " oat-celled " carcinoma, and (4) others, including " alveolar " cell carcinoma and carcinoma not classifiable. The histological classification of carcinoma of the bronchus is often difficult because of the existence of intermediate types and is somewhat arbitrary in some cases.
On the clinical side, a careful and full medical examination is made, including usually indirect laryngoscopy. It has been considered important to determine the extent of spread of the disease with special reference to the early detection of metastases in bones. The occasional cases originally considered inoperable and in which it has been found possible subsequently to carry out some type of surgery have been considered separately in the assessment of the results. The fate of every case included in the trial must be explicitly stated.
To obtain randomisation, the serial number of the patient in the special register of cases of inoperable carcinoma of the bronchus was taken and the corresponding number read off in a table of random numbers; (1948, p. 109) was used. For random numbers ending with an even number or zero, the patient was allocated to receive X-ray therapy combined with the compound administered by intravenous injection (X + I-VS) ; for odd random numbers, the patient was allocated to receive X-ray therapy combined with intramuscular compound (X + I-MS December, 1952 . Some cases are still surviving so that additional evidence concerning the diagnosis may be forthcoming in a few of these and the estimates of survival time are necessarily incomplete. It is reasonably certain that any such new evidence will increase the differences observed between the two series.
The total numbers of cases are 46 in the X + I-VS series, of which one received compound only with no X-ray therapy and 45 in the X + I-MS series. The fate of every case is accounted for in the Groups (a) to (j) of Table II . The small groups of male patients treated surgically at some stage (f) and female patients (h) are too heterogeneous and too small to be of value in investigation. Accurate diagnosis is of extreme importance in any studies of the treatment of carcinoma of the bronchus and appears to present greater difficulties than are commonly appreciated. The interpretation of bronchial biopsies is often difficult and review of the sections has led to rejection of the diagnosis of bronchial carcinoma in three cases (No. 45, 63, 68) . Positive histology on metastases in supraclavicular nodes, skin or bone is not necessarily evidence that the primary tumour is in a bronchus. Stringent criteria have been used in the cytological evaluation of malignant cells in sputum and bronchial aspirate. It is interesting that in Group (g) in which the diagnosis of bronchial carcinoma was unverified or probably incorrect, the results included some which at first consideration appeared to be among the most satisfactory.
The evidence to date presented in Table II shows that both for the selected treatable male patients with less advanced inoperable carcinoma of the bronchus in Groups (a), (b) and (c), and for all the male patients, not treated surgically and with reasonably certain diagnosis in the Groups (a), (b), (c), (d) and (e), a substantially larger proportion survive 8 months or more from the first X-ray treatment when this is combined with intravenous Compound I than when combined with intramuscular compound. The proportions are 11/14 for X + IV-S as compared with 4/19 for X + I-MS for pooled Groups (a), (b) and (c), and 13/26 for X + I-VS as compared with 4/30 for X + I-MS for the pooled Groups (a) to (e). Survival statistics are as yet incomplete but in the pooled Groups (a), (b) and (c)-with transfer of the case marked * to the X + I-MS series -the estimated survival time from the first X-ray treatment is significantly larger in the X + I-VS series (mean survival 10-8 months) than in the X + I-MS series (mean survival 5*9 months)-(n = 31, t = 2-701, so that P = 0-011).
As the number of cases increases, the significance of the various differences between the two series increases.
Survival from the first symptom is a less sensitive and less objective test. In some of the groups, the differences between the times of survival from the first symptom in the two series are suggestive but not really convincing. For the pooled Groups (a), (b), (c), (d) and (e), if the case marked * is transferred to the series X + I-MS, the proportions surviving 12 months or more from the 326 first recorded symptom in the series X + I-VS and X + I-MS are respectively 16/25 and 10/31; with Yates's correction for continuity X02 = 4-403 so that P = 0 037; thus the difference between these two groups can be regarded as significant.
It is necessary to consider the composition of the various groups in the two series in Table I . Histological classification is possible for all cases in Groups (a) and (b). There were no cases of adenocarcinoma. In the X + I-VS series, there were 9 cases of stratified carcinoma-7 squamous including one mixed formand 7/9 including one anaplastic carcinoma survived 8 months or more from the first X-ray treatment. In the X + I-MS series, there were 14 cases of stratified carcinoma of which 11 were squamous and of which only 4, 3 squamous and one non-squamous, survived 8 months or more from the first X-ray treatment. The difference in survival in these small groups in the two series is suggestive.
The methods of X-ray therapy and administration of the compound are not significantly different in the two series and fortunately such differences as are found might be considered as tending in all instances to reduce the observed differences in survival between the two series. Considering the Groups None of these differences between the two series is statistically significant.
For 31 degrees of freedom, for the differences for mean M.T.D., t = 0-924 and P = 0-36; for mean overall time of X-ray therapy t = 1*486, and P = 0-15, for mean amount of Compound t = 101 and P = 0-32; for mean overall time of administration of Compound t 1-602 and P = 0 11; and for mean age at the first treatment t = 1621 and P 0-11. Accordingly, it would appear to be justifiable to conclude that the results obtained so far in this clinical trial indicate that intravenous administration of Compound I (Synkavit) has a small but useful effect as a clinical radiosensitiser in the radiotherapy of inoperable cases of carcinoma of the bronchus. However, further evidence is desirable.
SUMMARY.
An attempt has been made to assess the clinical value of tetra-sodium 2-methyl-I: 4-naphthohydroquinone diphosphate (Synkavit) as a radiosensitiser in the radiotherapy of malignant tumours.
A preliminary general survey of the use of the compound in the treatment of patients with various types of malignant tumour other than carcinoma of the bronchus with follow-up for at least three and a half years is summarised. The results suggest that the proportion of cases showing unexpectedly good clinical response is greater with radiotherapy combined with the compound administered by intravenous injection than with radiotherapy combined with the compound administered by intramuscular injection.
Preliminary clinical studies of the influence of the ancillary use of the compound on the survival times of inoperable cases of carcinoma of the bronchus treated by X-ray therapy are discussed in some detail and the end results summarised.
The design of a clinical therapeutic trial of a radiosensitiser is discussed, with special reference to the evaluation of tetra-sodium 2-methyl-I: 4-naphthohydroquinone diphosphate M a radiosensitiser in the radiotherapy of inoperable cases of carcinoma of the bronchus. The results of this clinical trial are summarised to date.
It is concluded that intravenous administration of this compound (Synkavit) has a small but useful effect as a clinical radiosensitiser. 
